Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898542 | 1.00 | FLT3 (0.39) | FLT3GSK3BMAPK1GRM5ALDH1A1 | |
| SCHEMBL5757422 | 0.83 | MAPK1 (0.33) | MAPK1GRM5 | |
| SCHEMBL5757429 | 0.83 | MAPK1 (0.33) | MAPK1GRM5 | |
| SCHEMBL2889795 | 0.70 | GRM5 (0.46) | GRM5ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL2889796 | 0.70 | GRM5 (0.46) | GRM5ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL3107652 | 0.69 | PKM (0.46) | FLT3GSK3BGRM5ALDH1A1KMT2A | |
| SCHEMBL5822525 | 0.69 | MAPK1 (0.45) | FLT3GSK3BMAPK1GRM5ALDH1A1 | |
| SCHEMBL2889471 | 0.68 | ALDH1A1 (0.48) | FLT3GSK3BMAPK1GRM5ALDH1A1 | |
| SCHEMBL2893486 | 0.68 | HDAC2 (0.48) | ALDH1A1KMT2AATMKDM4ELMNA | |
| SCHEMBL2895448 | 0.68 | GRM5 (0.45) | FLT3GSK3BGRM5ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101845023-A | Tetrazole compound and as the application of metabotropic glutamate receptor antagonists | NPS PHARMA INC | 2010-09-29 | — | — | CN | claimed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | claimed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | claimed |
| CN-1918137-A | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | claimed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | claimed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | claimed |
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| CN-1918137-B | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2012-08-01 | — | — | CN | disclosed |
| CN-101845023-A | Tetrazole compound and as the application of metabotropic glutamate receptor antagonists | NPS PHARMA INC | 2010-09-29 | — | — | CN | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| CN-1918137-A | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | FLT3 604/4885GSK3B 3968/4885MAPK1 2164/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | FLT3 636/4885GSK3B 3964/4885MAPK1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.